IRGQ Knockout MCF-7 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population targeting the IRGQ gene in the MCF-7 breast cancer cell line. This loss-of-function model enables investigation of IRGQ-dependent processes. The polyclonal format preserves heterogeneous knockout effects, suitable for population-level gene disruption studies without single-cell cloning. Disrupting IRGQ, an immunity-related GTPase, facilitates research into autophagy and innate immune pathways in an estrogen receptor-positive breast cancer context.
The host cell line, MCF-7, is an extensively characterized epithelial cell line derived from a metastatic mammary adenocarcinoma pleural effusion. As an estrogen receptor-positive model, it faithfully retains key features of luminal breast cancer, including hormone responsiveness and retained epithelial characteristics. MCF-7 cells are widely used to study tumor cell biology, endocrine therapy resistance, and signaling networks relevant to breast cancer progression. Their well-documented genetic background and ease of manipulation make them a robust host for CRISPR/Cas9-mediated gene disruption studies.
IRGQ belongs to the immunity-related GTPase family and functions downstream of interferon-gamma (IFN-??) signaling, with its expression transcriptionally regulated by STAT1. It acts as a modulator of autophagy, a critical catabolic process governing cellular homeostasis, through interactions with core autophagy machinery components ATG5 and ATG16L1. IRGQ regulates key autophagy markers, including LC3B, the ubiquitin-binding scaffold protein p62/SQSTM1, and Beclin-1, a central initiator of autophagosome formation. Disruption of IRGQ disrupts the autophagy-mediated degradation pathway, potentially impeding the clearance of protein aggregates and damaged organelles, while concurrently dysregulating interferon-induced innate immune responses via altered feedback loops involving ULK1 and ATG7.
In the MCF-7 breast cancer environment, IRGQ knockout has profound implications for understanding autophagy-dependent survival mechanisms and tumor-immune interactions. Autophagy is often deregulated in cancer, contributing to drug resistance, metabolic adaptation, and immune evasion. By ablating IRGQ in an estrogen receptor-positive cell context, researchers can dissect how autophagy modulates response to hormonal therapies and chemotherapeutics. Additionally, the link between IRGQ and interferon signaling offers a unique opportunity to explore innate immune activation within the tumor microenvironment, particularly in the context of immunogenic cell death and antitumor immunity.
This knockout model supports a diverse array of experimental applications. Autophagic activity can be assessed by western blotting for LC3B lipidation and p62/SQSTM1 turnover, and autophagic flux quantified with bafilomycin A1 co-treatment. Immunofluorescence for LC3 puncta provides complementary cytological evidence. MTT assays link autophagy to cell viability and drug sensitivity, while RT-qPCR of interferon-stimulated genes dissects innate immune outcomes. These polyclonal IRGQ knockout cells serve as a versatile tool for breast cancer and infectious disease research. For additional information, contact Ascent Research.
